Takara Holdings Inc (Takara) controls and manages its group companies that manufacture and commercialize alcoholic beverages, seasonings, biomedicals and health foods. The company also operates in the biotechnology sector, providing reagents, instruments, and CDMO services. Takara serves industries such as food and beverage, biotechnology, and real estate.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Takara Holdings has undertaken strategic R&D initiatives through its Takara Bio Group, focusing on biotechnology. Takara Bio is actively developing reagents and instruments for genetic and cell engineering research and advancing its CDMO services to support regenerative and cellular medicine and gene therapy. The company is also enhancing its presence in the life sciences industry by leveraging synergies with newly consolidated companies like Curio Bioscience, Inc and ViSpot, Inc Despite challenges in the biotechnology landscape, Takara Bio is committed to maintaining its competitive edge through strategic R&D activities. The R&D unit of the company is the Takara Bio Group, which is responsible for managing the company's R&D activities, including the development of reagents and instruments for genetic and cell engineering research and advancing CDMO services for regenerative and cellular medicine and gene therapy. In FY2025, the company spent JPY7,309 million on its R&D activities, which as a percentage of revenue stood at 2%.